News
Hosted on MSN1mon
Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery - MSNTHURSDAY, May 15, 2025 (HealthDay News) -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity ...
Cite this: Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1–Stimulated Postprandial Insulin Secretion in Humans - Medscape - Sep 01, 2011. Abstract and Introduction Research Design and ...
People undergoing metabolic and bariatric surgery (MBS) are less likely to develop psychiatric disorders than those treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
More information: Yael Wolff Sagy et al, Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective ...
GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...
Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.
Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...
Combining elements of four hormones into a single drug, researchers hope a next-generation weight loss drug will address not only obesity, but associated conditions like type 2 diabetes, cancer, and ...
They’ve all been used to describe effects of the rapid weight loss that can come from taking glucagon-like peptide-1 receptor agonists like semaglutide, which is in Ozempic.
The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: a systematic review and meta-analysis. Br J Clin Pharmacol 2022;88:3627-3637. Crossref ...
The researchers found that over a median of 7.5 years, ORC occurred in 5.62 cases per 1,000 person-years in the BMS group and in 5.89 cases per 1,000 person-years in the GLP-1 RA group (adjusted ...
Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results